

## CV

**Name:** Yu-quan Wei

**Date of Birth:** June 4, 1959

**Nationality:** Chinese

**Address:** National Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Ke-yuan Road 4, No.1, Gao-peng Street, Chengdu, Sichuan, 610041, The People's Republic of China.

Phone: 86-28-85164059; Fax: 86-28-85164060

E-mail: yuquanwei@scu.edu.cn

### **Current Post:**

Chairman and Professor, National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan, The People's Republic of China.

Vice President, Sichuan University

Academician, Chinese Academy of Sciences

Vice President, Chinese Association of Medicine

Associate Editor of Human Gene Therapy

### **Education:**

1978-1983: Educated at West China University of Medical Sciences for Medical degree.

1983-1986: West China University of Medical Sciences for MS

1991-1996: Kyoto University in Japan for Ph.D in Medicine.

### **Professional Employment:**

1986–1989: Assistant teacher for pathology, West China University of Medical Sciences, Sichuan, China

1989–1991: Lecturer for pathology, West China University of Medical Sciences,

1996-1997: Associate Professor and Chairman in Laboratory of Biotherapy of Human Diseases, and Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University.

1997-2007, Professor and Chairman in Key Laboratory of Biotherapy and Department of Biotherapy, Cancer Center,, West China Hospital, West China Medical School, Sichuan University.

2007- Professor and Chairman in National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University.

### **Research:**

Interested in the development of gene and cell therapy, cancer vaccine, inhibition of angiogenesis, induction of apoptosis in tumor cells and clinical bio-chemotherapy.

***The selected publication:***

1. Xie C, Gou ML, Yi T, Deng H, Li ZY, Liu P, Qi XR, He X, Wei Y, Zhao X. Efficient Inhibition of Ovarian Cancer by Truncation Mutant of FILIP1L Gene Delivered by Novel Biodegradable Cationic Heparin-Polyethyleneimine Nanogels. *Hum Gene Ther*. 2011 Jun 8. [Epub ahead of print]
2. Wilson JM, Gansbacher B, Berns KI, Bosch F, Kay MA, Naldini L, Wei YQ. Good news on the clinical gene transfer front. *Hum Gene Ther*, 2008;19(5):429-30.
3. Yao SH, Qian ML, Deng SY, Xie LF, Yang HS, Xiao C, Zhang T, Xu H, Zhao X, Wei YQ, Mo XM. KZP controls canonical WNT8 signaling to modulate dorsoventral patterning during zebrafish gastrulation. *Journal of Biological Chemistry*. 2010, 285: 42086-42096.
4. Zhao JM, Wen YJ, Li Q, Wang YS, Wu HB, Xu JR, Chen XC, Wu Y, Fan LY, Yang HS, Liu T, Ding ZY, Du XB, Diao P, Li J, Kan B, Lei S, Deng HX, Mao YQ, Zhao X, Wei YQ. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. *Faseb Journal*. 2008, 22: 4272-4280.
5. Wang YS, Wang GC, Wen YJ, Wang L, Chen XC, Chen P, Kan B, Li J, Huang CH, Lu Y, Zhou C, Xu N, Li D, Fan LY, Yi T, Wu HB, Wei YQ. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFik-1. *Clinical Cancer Research*. 2007, 13: 6779-6787.
6. Wang YS, Li D, Shi HS, Wen YJ, Yang L, Xu N, Chen XC, Chen X, Chen P, Li J, Deng HX, Wang CT, Xie G, Huang S, Mao YQ, Chen LJ, Zhao X, Wei YQ. Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. *Clinical Cancer Research*. 2009, 15: 6901-6911.
7. Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, Li Q, He QM, Zhao X, Jiang Y, Li J, Deng HX, Kang B, Mao YQ, Wei YQ. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. *Clinical Cancer Research*. 2006, 12: 1813-1819
8. Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, Du XB, Wang GQ, Yao WX, Zhao QM, Ye B, Wang R, Diao P, Zhang W, Wu HB, Zhao X, Wei YQ. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. *Clinical Cancer Research*. 2006, 12: 3193-3199.
9. Zhao Z, Yao Y, Ding Z, Chen X, Xie K, Luo Y, Zhang J, Chen X, Wu X, Xu J, Zhao J, Niu T, Liu J, Li Q, Zhang W, Wen Y, Su J, Hu B, Bu H, Wei Y, Wu Y. Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin. *Vaccine*. 2011, 25:4218-24.
10. Zhao C, Wang X, Zhao Y, Li Z, Lin S, Wei Y, Yang H. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. *PLoS One*. 2011, 7:e21768.
11. Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C, Wei Y. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. *PLoS One*. 2011, 5:e20586.
12. Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, Xie N, Nai HS, Wu H,

- Dong Q, Zhao X, Nice EC, Huang C, Wei Y. Proteomics Identification of ITGB3 as a Key Regulator in Reactive Oxygen Species-induced Migration and Invasion of Colorectal Cancer Cells. *Mol Cell Proteomics*. 2011, 10.
13. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L, Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. *Clin Cancer Res*. 2011, 13:4439-50.
  14. Wang K, Liu R, Li J, Mao J, Lei Y, Wu J, Zeng J, Zhang T, Wu H, Chen L, Huang C, Wei Y. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1 $\alpha$ -mediated signaling. *Autophagy*. 2011, 9:966-78.
  15. Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J, Wang N, Peng C, Zhao X, Wei Y, Chen L. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. *PLoS One*. 2011, 4:e18490.
  16. Zhao C, Yang H, Shi H, Wang X, Chen X, Yuan Y, Lin S, Wei Y. Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases. *Carcinogenesis*. 2011, 8:1143-50.
  - 17.
  18. Liu XY, Wen FQ, Yang JL, Chen LJ, Wei YQ. A review of current applications of mass spectrometry for neuroproteomics in epilepsy. *Mass Spectrometry Reviews*. 2010, 29: 197-246.
  19. Li ZY, Zhao X, Bai SJ, Wang Z, Chen LJ, Wei YQ, Huang CH. Proteomics identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. *Molecular & Cellular Proteomics*. 2008, 7: 1810-1823.
  20. Liu R, Li ZJ, Bai SJ, Zhang HY, Tang MH, Lei YL, Chen LJ, Liang SF, Zhao YL, Wei YQ, Huang CH. Mechanism of cancer cell adaptation to metabolic stress proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. *Molecular & Cellular Proteomics*. 2009, 8: 70-85.
  21. Stmad P, Tao GZ, So P, Lau K, Schilling J, Wei Y, Liao J, Omary MB. "Toxic Memory" via chaperone modification is a potential mechanism for rapid Mallory-Denk body reinduction. *Hepatology*. 2008, 48: 931-942.
  22. Gou ML, Men K, Zhang JA, Li YH, Song J, Luo S, Shi HS, Wen YJ, Guo G, Huang MJ, Zhao X, Qian ZY, Wei YQ. Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. *ACS Nano*. 2010, 4: 5573-5584.
  23. Fang F, Gong CY, Qian ZY, Zhang XN, Gou ML, You C, Zhou LX, Liu JG, Zhang Y, Guo G, Gu YC, Luo F, Chen LJ, Zhao X, Wei YQ. Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion. *ACS Nano*. 2009, 3: 4080-4088.
  24. Li JY, Liu R, Lei YL, Wang K, Lau QC, Xie N, Zhou ST, Nie CL, Chen LJ, Wei YQ, Huang CH. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. *Autophagy*. 2010, 6: 711-724.
  25. Tao GZ, Looi KS, Toivola DM, Strnad P, Zhou Q, Liao J, Wei YQ, Habtezion A, Omary MB. Keratins modulate the shape and function of hepatocyte mitochondria: a mechanism for protection from apoptosis. *Journal of Cell Science*. 2009, 122: 3851-3855.
  26. Chen XA, Wang XH, Wang YS, Yang L, Hu J, Xiao WJ, Fu A, Cai LL, Li X, Ye X, Liu YL, Wu WS, Shao XM, Mao YQ, Wei YQ, Chen LJ. Improved tumor-targeting drug delivery and

- therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. *Journal of Controlled Release*. 2010, 145: 17-25.
27. Wang W, Gou LT, Xie G, Tong AP, He F, Lu ZJ, Yao YQ, Liu K, Li J, Tang MH, Chen LJ, Yang JL, Hu HZ, Wei YQ. Proteomic analysis of interstitial fluid in bone marrow identified that peroxiredoxin 2 regulates h2o2 level of bone marrow during aging. *Journal of Proteome Research*. 2010, 9: 3812-3819.
  28. Chen XC, Wang R, Zhao X, Wei YQ, Hu M, Wang YS, Zhang XW, Zhang R, Zhang L, Yao B, Wang L, Jia YQ, Zeng TT, Yang JL, Kan B, Lin XJ, Lei S, Deng HX, Wen YJ, Mao YQ, Li J. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. *Carcinogenesis*. 2006, 27: 2434-2441.
  29. Tong AP, Gou LT, Lau QC, Chen B, Zhao X, Li J, Tang H, Chen LJ, Tang MH, Huang CH, Wei YQ. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis b virus x protein. *Journal of Proteome Research*. 2009, 8: 1037-1046.
  30. Ren FL, Wu H, Lei YL, Zhang HY, Liu R, Zhao Y, Chen XC, Zeng DQ, Tong AP, Chen LJ, Wei YQ, Huang CH. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. *Molecular Cancer*. 2010, 9: 81.
  31. Du XB, Lang JY, Xu JR, Lu Y, Wen YJ, Zhao JM, Diao P, Yuan ZP, Yao B, Fan LY, Wang GQ, Liu L, Ding ZY, Wang YS, Li T, Wang R, Mao YQ, Kan B, Wu HB, Li HX, Yang HS, Wei YQ, Zhao X. Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. *Apoptosis*. 2008, 13: 1205-1214.
  32. Xu N, Wang YS, Pan WB, Xiao B, Wen YJ, Chen XC, Chen LJ, Deng HX, You J, Kan B, Fu AF, Li D, Zhao X, Wei YQ. Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. *Molecular Cancer Therapeutics*. 2008, 7: 1588-1597.
  33. Ding ZY, Wu Y, Luo Y, Su JM, Li Q, Zhang XW, Liu JY, He QM, Yang L, Tian L, Zhao X, Deng HX, Wen YJ, Li J, Kang B, Wei YQ. Mannan-modified adenovirus as a vaccine to induce antitumor immunity. *Gene Therapy*. 2007, 14: 657-663.
  34. Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X, Wei YQ. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. *International Journal of Cancer*. 2009, 124: 2709-2718.
  35. Li ZY, Huang CH, Bai SJ, Pan XL, Zhou R, Wei YQ, Zhao X. Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. *International Journal of Cancer*. 2008, 123: 2377-2383.
  36. Hu J, Ye HY, Fu A, Chen XA, Wang YS, Chen XC, Ye X, Xiao WJ, Duan XM, Wei YQ, Chen LJ. Deguelin-an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model. *International Journal of Cancer*. 2010, 127: 2455-2466.
  37. Zhang R, Tian L, Chen LJ, Xiao F, Hou JM, Zhao X, Li G, Yao B, Wen YJ, Li J, Zhang L, Chen XC, Luo F, Peng F, Jiang Y, Wei YQ. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. *Gene Therapy*. 2006, 13: 1263-1271.
  38. Yang LJ, Zou J, Xie HZ, Li LL, Wei YQ, Yang SY. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. *Plos One*. 2009, 4.
  39. Wang XH, Zhou JC, Wang YS, Zhu ZY, Lu Y, Wei YQ, Chen LJ. A phase I clinical and

- pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. *European Journal of Cancer*. 2010, 46: 1474-1480.
40. Wu Y, Li ZY, Zhao X, Kan B, Wei YQ. Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. *Human Gene Therapy*. 2006, 17: 941-948.
  41. Yang SY, Xiang ML, Chen LJ, Xie GB, Shi B, Wei YQ, Ziegler T. Free energy profiles for monomer capture in Grubbs- and SHOP-type olefin polymerization catalysts: A constraint ab initio molecular dynamics study. *Journal of Computational Chemistry*. 2007, 28: 513-518.
  42. Ding ZY, Wei YQ. Therapeutic vaccine for melanoma: the untouched grail? *Expert Review of Vaccines*. 2007, 6: 907-911.
  43. Deng XQ, Wang HY, Zhao YL, Xiang ML, Jiang PD, Cao ZX, Zheng YZ, Luo SD, Yu LT, Wei YQ, Yang SY. Pharmacophore modelling and virtual screening for identification of new aurora-a kinase inhibitors. *Chemical Biology & Drug Design*. 2008, 71: 533-539.
  44. Wang HY, Li LL, Cao ZX, Luo SD, Wei YQ, Yang SY. A specific pharmacophore model of aurora b kinase inhibitors and virtual screening studies based on it. *Chemical Biology & Drug Design*. 2009, 73: 115-126.
  45. Li R, Chen W, Shi JY, Chen LJ, Chen YC, Ding LS, Wei YQ. Discovery and synthesis of a new bis(thiourea)-Pd pincer guided by ESI-MS/MS. *Journal of Mass Spectrometry*. 2008, 43: 542-546.
  46. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li J, Niu T, Yang JL. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. *J Biol Chem*. 2003, 24:21831-6.
  47. Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B, Kan B, Wen YJ, Liu F, Deng HX, Li J, Mao YQ, Lei S, Huang MJ, Peng F, Jiang Y, Zhou H, Zhou LQ, Luo F. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. *J Immunol*. 2003, 6:3162-70.
  48. Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng HX, Li J, Kan B. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. *Cancer Res*. 2003, 3:600-7.
  49. Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, Wen YJ, Xiao F, Yao B, Zhang R, Peng F, Jiang Y, Luo F, Zhao X, Zhang L, Zhou Q, Wei YQ. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. *Clin Cancer Res*. 2005, 11:4217-24.
  50. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F, Peng F. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. *Blood*. 2003, 5:1815-23. Yu-quan Wei, Qing-ru Wang, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. *Nature Medicine*, 2000; 6(10): 1160-1166.
  51. Yu-quan Wei, Mei-juan Huang, et al. Immunogene therapy of tumors with vaccine based on xenopus homologous vascular endothelial growth factor as a model antigen. *Proc. Natl. Acad. Sci. USA*. 2001; 98(20): 11545-11550.

